Bai SJ, Ma L, Luo M, Xu H, Yang L. Management about intravesical histological transformation of prostatic mucinous carcinoma after radical prostatectomy: A case report. World J Clin Cases 2022; 10(14): 4654-4660 [PMID: 35663096 DOI: 10.12998/wjcc.v10.i14.4654]
Corresponding Author of This Article
Lu Yang, PhD, Assistant Professor, Chief Doctor, Department of Urology, Institute of Urology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Wuhou District, Chengdu 610041, Sichuan Province, China. wycleflue@163.com
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. May 16, 2022; 10(14): 4654-4660 Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4654
Management about intravesical histological transformation of prostatic mucinous carcinoma after radical prostatectomy: A case report
Sheng-Jiang Bai, Li Ma, Min Luo, Hang Xu, Lu Yang
Sheng-Jiang Bai, Li Ma, Min Luo, Hang Xu, Lu Yang, Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Bai SJ reviewed all the literature available about prostate mucinous carcinoma and mucinous carcinoma with signet ring cells up until June 2021 and was a major contributor to the manuscript; Ma L performed the literature review and made critical revisions of the manuscript; Luo M and Xu H performed the data acquisition and contributed to partial writing of the manuscript; Yang L guided throughout the writing process as well as funded the project; All authors read and approved the final manuscript.
Supported byScience and Technology Department of Sichuan Province, No. 21GJHZ0246.
Informed consent statement: Written informed consent for publication of the patient’s clinical details and clinical images was obtained from the patient.
Conflict-of-interest statement: The authors declare no potential conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lu Yang, PhD, Assistant Professor, Chief Doctor, Department of Urology, Institute of Urology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Wuhou District, Chengdu 610041, Sichuan Province, China. wycleflue@163.com
Received: November 24, 2021 Peer-review started: November 24, 2021 First decision: January 22, 2022 Revised: February 5, 2022 Accepted: March 16, 2022 Article in press: March 16, 2022 Published online: May 16, 2022
Abstract
BACKGROUND
Prostatic mucinous carcinoma (MC) and prostatic signet ring cell carcinoma are two variants of prostate cancer. MC has a higher overall survival time among all variants, while signet ring cell carcinoma is associated with lower survival time relative to other carcinomas. Only a small proportion of prostatic MC may contain signet ring cells. Over the last several decades there were only 12 patients that were documented in two studies.
CASE SUMMARY
We report on a 64-year-old man who was diagnosed with prostatic MC after he received a robotic-assisted laparoscopic radical prostatectomy in the West China Hospital. After robotic-assisted laparoscopic radical prostatectomy, the patient underwent three successive transurethral resections of bladder tumors. Pathological examination of the first transurethral resection of bladder tumors specimen indicated that the neoplasm was prostatic MC that had metastasized to the urinary bladder. The subsequent two transurethral resections of bladder tumors indicated the presence of prostatic mucinous carcinoma with signet ring cells.
CONCLUSION
This case report aimed to share the management experience, raise awareness, and highlight the importance of multidisciplinary cooperation of prostatic mucinous carcinoma with signet ring cells.
Core Tip: Prostatic mucinous carcinoma with signet ring cells (MCSRC) is a very rare morphologic variant of prostate cancer. Previously, only 12 patients have been reported, all of whom were diagnosed during the first prostate surgery. In this study, we report the first case of prostatic MCSRC that developed from the long course of prostatic mucinous carcinoma; the histological transformation was extremely uncommon. Because therapy of prostatic MCSRC is tricky and prognosis is worse, we share the management experience, raise awareness, and highlight the early and active treatment intervention for recurrent prostate mucinous carcinoma and prostatic MCSRC with multidisciplinary cooperation.
